Avanos Medical, Inc. (NYSE: AVNS) reported Q2 EPS of $0.24, $0.09 worse than the analyst estimate of $0.33. Revenue for the quarter came in at $169.4 million versus the consensus estimate of $193.75 million.

GUIDANCE:

Avanos Medical, Inc. sees FY2023 EPS of $1.05-$1.15, versus the consensus of $1.52.

For earnings history and earnings-related data on Avanos Medical, Inc. (AVNS) click here.